Recent advance in treatment of refractory myasthenia gravis
10.3760/cma.j.issn.1671-8925.2016.03.023
- VernacularTitle:难治性重症肌无力治疗的研究进展
- Author:
Lin LEI
1
;
Yuwei DA
Author Information
1. 首都医科大学宣武医院神经内科
- Keywords:
Myasthenia gravis;
Refractory;
Treatment
- From:
Chinese Journal of Neuromedicine
2016;15(3):319-321
- CountryChina
- Language:Chinese
-
Abstract:
Myasthenia gravis is an autoimmune disease involving the acquired neuromuscular junction.Vast majority of patients with myasthenia gravis after conventional treatment (acetylcholinesterase inhibitors,plasmapheresis,gammaglobulin,and immunosuppressants) has significantly improved prognosis;but,there is still a small portion of patients had refractory myasthenia gravis,they did not have effective treatment,and their prognosis is poor.Some recent studies suggest that novel immunomodulatory agents,secondary thymus expand dissection,hematopoietic stem cell transplantation may be in force.
